In this study, we show that hepatic Gcgr signaling regulates PCSK9 and thereby contributes to plasma LDL-C homeostasis. Mechanistically, we report that Gcgr signaling regulates PCSK9 through the Epac2 (exchange protein activated by cAMP-2) and Rap1 (ras-related protein-1) pathway. Finally, we provide evidence that glucagon regulates the stability of PCSK9 protein without changing the level of its mRNA through promoting its lysosomal degradation. Together, our findings reveal the Gcgr-Epac2-Rap1 pathway as a novel regulator of PCSK9 and circulating LDL-C levels.
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Reagents and Antibodies
Glucagon, forskolin, dexamethasone, cycloheximide, chloroquine, ammonium chloride, and H89 were from Sigma. Anti-β-actin antibodies were from Cell Signaling Technology (catalog number 4970) and Sigma (catalog number A3854). Anti-LDLR antibody was from Abcam (catalog number ab30532). Anti-Pan-Cadherin antibody was from Cell Signaling Technology (catalog number 4068). Anti-PCSK9 antibody used for Western blotting was from R&D Systems (catalog number AF3985). Anti-Hsp90 (heat shock protein 90) antibody was from Cell Signaling Technology (catalog number 4877). Specific Epac activator 8-pCPT-2-O-Me-cAMP-AM was from Tocris. Adenoassociated virus 8 (AAV8)-short hairpin RNA constructs targeting murine Gcgr, PCSK9, Epac2 (Rapgef4 [rap guanine nucleotide exchange factor 4]), and Rap1a were made by annealing complementary oligonucleotides and then ligating them into the pAAV-RSV-GFP-H1 vector, as described previously. 23 5'-TGGTCAAGTGTCTGTTTGA-3', 5'-CAGAGGCTACAGATTGAACAA-3', 5'-GTGGTGCTGAAAT CTAATGAT-3', and 5'-GCTCAGTCTACGTTTAATGAT-3' were short hairpin RNA target sequences for Gcgr, PCSK9, Epac2, and Rap1a, respectively. The resultant constructs were amplified by Salk Institute Gene Transfer, Targeting, and Therapeutics Core. Small interfering RNA sequence against murine Rapgef4 (Epac2) was purchased from Integrated DNA Technologies. Adenoviruses encoding Rap1Gap (Rap1 GTPase activating protein) and constitutively active Rap1a (CA-Rap1a) were described previously 24, 25 and amplified and purified by Viraquest, Inc (North Liberty, IA). Anti-Gcgr (REGN1193) and anti-PCSK9 (REGN727) antibodies administered in mice have been described previously. 26, 27 
Mouse Experiments
Wild-type (WT; stock number: 000664), ob/ob (stock number: 000632), Ldlr −/− (stock number: 002207), Pcsk9 −/− (stock number 005993), and diet-induced obese (DIO, stock number: 380050) mice were from Jackson Labs. In some experiments, WT C57BL/6NTac from Taconic (B6-M) were used, as indicated in the corresponding legends. Gcg −/− mice were generated as described previously. 28 DIO mice were fed a high-fat diet with 60% kcal from fat (Research Diets). To avoid the effects of sex-related differences in metabolism, male mice were used for the majority of the experiments. All mice were maintained on a 12 hour-light/dark cycle. 
Novelty and Significance
What Is Known?
• LDLR (low-density lipoprotein receptor) binds atherogenic LDL particles.
• PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibits the liver's ability to clear LDL-C (LDL cholesterol) from the plasma through regulating hepatic LDLR levels.
• The fasting hormone glucagon contributes to LDL-C homeostasis;
however, in-depth mechanistic information is lacking.
What New Information Does This Article Contribute?
• Inhibition of glucagon action increases plasma LDL-C through increasing PCSK9 levels, whereas glucagon treatment lowers PCSK9 and plasma LDL-C.
• Glucagon signaling regulates PCSK9 through its downstream mediators, Epac2 (exchange protein activated by cAMP-2) and Rap1 (rasrelated protein-1).
• Glucagon regulates PCSK9 protein stability.
Inhibition of PCSK9 has emerged as an attractive target for LDL-C lowering therapy, but the mechanisms underlying PCSK9 regulation are poorly understood. Using different genetic and pharmacological models, we show that deficiency or inhibition of hepatic glucagon signaling increases plasma LDL-C and PCSK9, whereas glucagon treatment has the opposite effects. Notably, the effect of blocking glucagon action on increasing plasma LDL-C is abrogated by inhibition or deficiency of PCSK9, indicating that the effect of glucagon on plasma LDL-C requires PCSK9. Glucagon, acting through its downstream mediators Epac2 and Rap1, enhances lysosomal degradation of PCSK9. As such, glucagon's ability to decrease PCSK9 levels is mimicked by expressing a constitutively active Rap1 in the liver. These results increase our understanding of the molecular mechanisms regulating PCSK9 levels and identify novel targets for LDL-C homeostasis.
(1-2×10 11 genome copy per mouse) and adenoviruses (0.5-0.75×10 9 plaque-forming units per mouse) were delivered by tail vein injections, and experiments were commenced after 3 to 28 days. Mice were injected subcutaneously with 50 ng per g body weight of glucagon (Sigma) or vehicle (5% acetic acid) in 5% gelatin 3× daily for 3 days, as described. 10, 29 For all experiments, male mice of the same age and similar weight were randomly assigned to experimental and control groups. Animal experiments were blinded with an internal number, and investigators were blinded to the group allocation during the experiment. Animal group sizes were estimated by power analysis based on previous experiments using similar methodologies.
Statistical Analysis
All results are presented as mean±SEM. Normality of data distributions was assessed using Shapiro-Wilk normality test. P values were calculated using the Student t test for normally distributed data and the Mann-Whitney U test for nonnormally distributed data. For experiments with >2 groups, P values were calculated using 1-way ANOVA. Data with 2 independent variables were analyzed by 2-way ANOVA; a threshold of P<0.05 was considered statistically significant.
Study Approval
Animal studies were conducted in accordance with the Columbia University Medical Center Animal Care and Use Committee and Regeneron Institutional Animal Care and Use Committee.
Results

Hepatic Gcgr Signaling Affects Plasma LDL-C Through Regulating LDLR and PCSK9 Protein Levels In Vivo
To investigate the role of hepatic Gcgr signaling in cholesterol metabolism, we used 3 different models to inhibit glucagon action. In the first model, we treated DIO mice with AAV8 in which short hairpin RNA targeting the Gcgr (shGcgr) was driven by the H1 promoter that silences genes in the liver. 23, 30 This treatment lowered hepatic Gcgr levels by ≈80% ( Figure 1A ), and consistent with previous reports, 31, 32 it lowered fasting blood glucose levels from 189±9 to 142±7 mg/dL ( Figure 1B ). Reduced hepatic Gcgr expression did not affect body weight or plasma insulin in the obese mice (Online Figure IA and IB) . Gcgr silencing increased plasma total cholesterol (88±6 versus 122±7 mg/dL; Figure 1C ) but did not affect plasma triglycerides (Online Figure IC) . Fast protein liquid chromatography analysis of the plasma revealed the specific increase in LDL-C in sh-Gcgr-treated mice compared with the control group, with no change in VLDL-C (very low-density lipoprotein cholesterol) or HDL-C (high-density lipoprotein cholesterol; Figure 1D ). In search for the mechanism of the increase in LDL-C in sh-Gcgr-treated mice, we found that inhibition of hepatic Gcgr significantly lowered LDLR protein levels, without a decrease in the mRNA expression of Ldlr or cholesterol synthesis genes ( Figure 1E and Online Figure ID) . We observed that Gcgr inhibition had similar effects in genetically obese (ob/ob) and WT lean mice; that is, it decreased hepatic LDLR protein and increased plasma total cholesterol (Online Figure IE and IF) . To examine whether the increase in plasma LDL-C requires LDLR, we silenced hepatic Gcgr in LDLR knockout (Ldlr −/− ) mice (Online Figure  IIA and IIB). Although blocking glucagon action lowered blood glucose levels (162±9 versus 111±8 mg/dL), no significant changes in plasma lipids were observed between control versus sh-Gcgr-treated Ldlr −/− mice, suggesting that glucagon action regulates LDL-C through LDLR (Online Figure   IIC -IIF). PCSK9 enhances the degradation of LDLR both extra-and intracellularly and contributes to LDL-C homeostasis. 33 We, therefore, hypothesized that the increase in LDL-C in the sh-Gcgr-treated mice was because of an increase in circulating PCSK9. 5 In support of this idea, we observed that the decrease in hepatic LDLR in Gcgr-silenced mice correlated with an increase in circulating PCSK9 levels (295±42 versus 597±62 ng/mL; Figure 1F ). As liver is the major source of circulating PCSK9, 34 we next measured liver PCSK9 levels and found that sh-Gcgr treatment significantly increased PCSK9 protein without a change in corresponding mRNA levels ( Figure 1G and Online Figure IIIA , note that the specificity of PCSK9 antibody for Western blotting was assessed using primary hepatocytes from Pcsk9 −/− mice in Online Figure IIIB ). Furthermore, mRNA levels of transcription factors known to regulate PCSK9, namely Srebf2 and Hnf1a, 35 did not change upon sh-Gcgr treatment (Online Figure IIIC) . Finally, we observed that Gcgr inhibition increased circulating and hepatic PCSK9 in ob/ob (211±35 versus 370±20 ng/mL) and WT lean mice (127±6 versus 174±6 ng/mL; Online Figure IIID 
-IIIG).
In the second model, we treated WT lean and DIO mice with a monoclonal blocking antibody against Gcgr. 26 Likewise, this treatment effectively lowered blood glucose and resulted in increased plasma LDL-C and plasma PCSK9 (247±25 versus 352±28 ng/mL) without a change in hepatic Pcsk9, Ldlr, Hnf1a, and Srebf2 mRNA levels (Online Figure  IV) . Importantly, similar increases in plasma LDL-C (9.6±0.4 versus 15±1.4 mg/dL) and PCSK9 levels (218±11 versus 357±24 ng/mL) were found in glucagon deficient (Gcg −/− ) mice 28 suggesting that glucagon action is required for this regulation (third model; Online Figure V ).
To test whether increased plasma cholesterol seen with hepatic Gcgr deficiency was dependent on the increase in PCSK9, we silenced both hepatic Gcgr and PCSK9 in obese mice using AAV8-sh vectors. As designed, the level of plasma PCSK9 in these mice was similar to that in control mice treated with nonsilencing, control AAV8 (Figure 2A and 2B). Consistent with the Gcgr-PCSK9 hypothesis, PCSK9 silencing prevented the increases in plasma LDL-C and total cholesterol that we observe with Gcgr silencing, whereas it did not affect the blood glucose-lowering effect of sh-Gcgr treatment ( Figure 2C-2E) . Similarly, anti-Gcgr antibody-treated mice had higher levels of total and LDL-C than control mice, and in response to inhibition of circulating PCSK9 via anti-PCSK9 antibody treatment, this increment was abolished (Online Figure VI ). More importantly, absence of PCSK9 completely abrogated the ability of Gcgr silencing to increase plasma LDL-C as sh-Gcgr treatment had no effect on plasma LDL-C (3.6±1.1 versus 3.9±1.2 mg/dL) in Pcsk9 −/− mice (Online Figure VII ) which may suggest a role for intracellular PCSK9 in LDLR and LDL-C regulation. 33 To further understand the contribution of glucagon action to PCSK9 and LDL-C metabolism, we injected WT mice with glucagon for 3 days. Consistent with previous reports, 14 we observed a significant decrease in plasma PCSK9 (199±20 versus 111±13 ng/mL) and LDL-C (11.0±0.6 versus 7.2±0.4 mg/dL) without a change in VLDL-C, HDL-C or body weight ( Figure 3A-3D) . However, this response was completely abrogated in the absence of LDLR or PCSK9 because glucagon treatment had no effect on plasma LDL-C in Ldlr −/− ( Figure 3E -3G) or Pcsk9 −/− mice ( Figure 3H-3J ). Taken together, these data suggest that hepatic Gcgr signaling affects LDLR and plasma LDL-C through regulating PCSK9 protein levels.
Glucagon Signaling Regulates PCSK9 Levels in Isolated Hepatocytes
To confirm the regulation of PCSK9 by glucagon signaling is cell intrinsic to hepatocytes, we moved to an in vitro model using both AML12 (alpha mouse liver 12) cells or primary murine hepatocytes and assayed PCSK9 expression in cells treated with control or sh-Gcgr containing plasmids. Consistent with the in vivo results, Gcgr silencing increased secreted PCSK9 protein without altering Pcsk9 mRNA levels (Online Figure  VIIIA-VIIIC) . We next examined whether glucagon regulates PCSK9 levels in primary hepatocytes. Again, we observed that glucagon treatment resulted in decreased PCSK9 protein levels without changing Pcsk9 mRNA ( Figure 4A and 4B) , further supporting the link between glucagon action and PCSK9.
Upon binding to its receptors, glucagon activates adenylate cyclase which increases intracellular cAMP. Increased cAMP activates both PKA (protein kinase A), which promotes Figure 1 . Hepatic Gcgr (glucagon receptor) silencing increases LDL-C (low-density lipoprotein cholesterol), decreases hepatic LDLR (LDL receptor) protein, and increases hepatic and circulating PCSK9 (proprotein convertase subtilisin/kexin type 9) in diet-induced obese (DIO) mice. Twenty-weekold DIO mice were injected with adeno-associated virus 8 (AAV8) vectors containing short hairpin RNA (shRNA) against Gcgr (AAV8-shRNA targeting the Gcgr [sh-Gcgr]) or empty control AAV (AAV8-con). Liver Gcgr mRNA levels (A), 5-h fasting blood glucose (B), and plasma total cholesterol (TC) levels were measured (C); plasma lipoproteins were separated by fast protein liquid chromatography (D), liver LDLR protein levels were analyzed (E), plasma PCSK9 levels were measured (F), and hepatic PCSK9 protein was analyzed (G). Densitometric quantification of the immunoblot data are shown in the graphs. n=6, mean±SEM, *P<0.05; by unpaired, 2-tailed Student t test. HDL indicates high-density lipoprotein; and VLDL, very low-density lipoprotein.
gluconeogenesis and glycogenolysis and exchange factor activated by cAMP (Epac), which promotes hepatocyte survival. [36] [37] [38] As a first step in investigating whether cAMP was involved in Gcgr-mediated PCSK9 regulation, we showed that the combination of forskolin, an adenylate cyclase activator with dexamethasone, which downregulates cAMP-phosphodiesterase, 39 lowered both intracellular and secreted PCSK9 without changing Pcsk9 mRNA ( Figure 4C-4E ). Consistent with a decrease in PCSK9, this treatment also increased LDLR protein but not Ldlr mRNA ( Figure 4F and 4G) . To examine the contribution of PKA in PCSK9 regulation, we pretreated the hepatocytes with H89, a cell-permeable PKA inhibitor. 40 The efficiency of PKA inhibition Figure 2 . Increased plasma cholesterol by hepatic Gcgr (glucagon receptor) silencing is abrogated by also silencing PCSK9 (proprotein convertase subtilisin/kexin type 9) in diet-induced obese (DIO) mice. Twenty-week-old DIO mice were injected with empty adeno-associated virus 8 (AAV; AAV8-con), AAV8-short hairpin RNA targeting the Gcgr (sh-Gcgr) or AAV8-sh-Gcgr together with AAV8-sh-Pcsk9. Liver Gcgr mRNA levels were analyzed (A), plasma PCSK9 (B), 5-h fasting blood glucose (C), and plasma total cholesterol (TC) levels were measured (D), and plasma lipoproteins were separated by fast protein liquid chromatography (E). n=5-6, mean±SEM, *P<0.05, by 1-way ANOVA. HDL indicates high-density lipoprotein; LDL, low-density lipoprotein; and VLDL, very low-density lipoprotein.
by H89 was verified by its ability to suppress glucagon-induced phosphorylation of the PKA substrate, CREB (cAMP response element binding protein; data not shown). However, glucagon or cAMP-mediated decrease in PCSK9 was not reversed by PKA inhibition ( Figure 4H and 4I), suggesting that PKA is not involved in glucagon/cAMP-mediated PCSK9 regulation.
Gcgr-cAMP Regulates PCSK9 and LDLR Through Epac2 and Rap1
We next turned our attention to the PKA-independent mediator of cAMP, Epac2, which is the major Epac isoform expressed in hepatocytes. 37 We observed that the ability of Gcgr silencing to increase intracellular and secreted PCSK9 protein without altering Pcsk9 mRNA levels was mimicked by hepatocytes lacking Epac2 (Figure 5A-5D ). In line with an increase in PCSK9, Epac2 silencing led to decreased LDLR protein without a change in its mRNA levels ( Figure 5E-5F ). Conversely, treatment with a specific, cell-permeable Epac activator, 8-pCPT-2-O-MecAMP-AM, 41 lowered secreted PCSK9 in WT hepatocytes ( Figure 5G ), supporting the contribution of Epac2 in Gcgrmediated PCSK9 regulation. Ten-week-old WT C57BL/6J lean mice were injected with vehicle or glucagon for 3 d as described in Methods. Body weight (A), plasma glucagon (B), and plasma PCSK9 (proprotein convertase subtilisin/kexin type 9; C) levels were analyzed, and plasma lipoprotein levels were measured after ultracentrifugation (D). n=7, mean±SEM, *P<0.05, by unpaired, 2-tailed Student t test and Mann-Whitney U test. E-J, Similar to (A-D) except that Ldlr −/− (E-G) or Pcsk9 −/− (H-J) mice were used. n=6, mean±SEM, *P<0.05, by unpaired, 2-tailed Student t test or Mann-Whitney U test. HDL indicates high-density lipoprotein; and VLDL, very low-density lipoprotein.
Epac2 is a cAMP-responsive GEF (guanine nucleotide exchange factor) for Ras-like small GTPase family member, Rap1, which is activated by glucagon in hepatocytes. 38, 42 We next asked whether Rap1, acting downstream of Epac2, is involved in the regulation of PCSK9 by glucagon signaling. Silencing of Rap1a in hepatocytes led to a significant increase in PCSK9 protein levels without a change in its mRNA ( Figure 6A ). Rap1 cycles between an active GTPbound and inactive GDP-bound conformation. 43 To assess the functional role of Rap1 in the regulation of PCSK9 and cholesterol metabolism in vivo, we treated DIO mice with an adenovirus expressing the Rap1Gap which catalyzes Figure 4 . Glucagon (Gluc) signaling regulates PCSK9 (proprotein convertase subtilisin/kexin type 9) levels in isolated hepatocytes (HCs). A, PCSK9 and β-actin were probed from wild-type (WT) primary HCs treated with vehicle (Veh) or Gluc for 3 or 6 h in serum-free media. B, Pcsk9 mRNA was measured from WT HCs treated with Gluc for 6 h. C, AML12 (alpha mouse liver 12) HCs were incubated with forskolin (Fors) and dexamethasone (Dex) for 6 h in serum-free media. Cell extracts were probed for PCSK9 and β-actin. Densitometric quantification of the immunoblot data is shown in the graph. D, AML12 HCs were incubated with Fors and Dex or Veh in serum-free medium for 24 h. Secreted PCSK9 levels in culture media were analyzed by ELISA and normalized to intracellular protein concentration. Data are presented as arbitrary units (AU) relative to control. E, Pcsk9 mRNA was analyzed from WT primary HCs incubated with Fors and Dex or Veh control for 5 h in serum-free media. F, Similar to (D), except that LDLR (low-density lipoprotein receptor) and β-actin levels were analyzed. Densitometric quantification of the immunoblot data is shown in the graph. G, Similar to (E), except that Ldlr mRNA was analyzed. H, Similar to (D), except that cells were pretreated with or without PKA (protein kinase A) inhibitor, H89, for 1 h and incubated with Gluc or Veh for 24 h. I, Primary HCs were pretreated with or without PKA inhibitor, H89, for 1 h. Cells were then incubated with Fors and Dex for 14 h in serum-free media, and intracellular PCSK9 levels were analyzed. Densitometric quantification of the immunoblot data is shown in the graph. n=3-5 wells of cells per group; mean±SEM; *P<0.05; by unpaired, 2-tailed Student t test; Mann-Whitney U test; 1-way ANOVA or 2-way ANOVA.
the hydrolysis of bound GTP to GDP and inhibits Rap1. 24 Consistent with the in vitro data, when Rap1 activity was inhibited in liver, plasma PCSK9 levels were increased (145±16 versus 365±19 ng/mL) and liver LDLR protein was decreased ( Figure 6B and 6C) . Moreover, both total-and LDL-C levels were significantly increased in mice injected with Rap1Gap without a change in the mRNA levels of hepatic Ldlr, Pcsk9, Hmgcr, or Srebf2 (Figure 6D-6F) . Similar results were obtained when Rap1Gap was overexpressed in WT lean mice liver (Online Figure IX) .
We next examined the effect of activated hepatic Rap1 in vivo by treating DIO mice with an adenovirus encoding CARap1a. CA-Rap1a possesses an amino acid substitution, Q63E, which confers constitutive GTP-binding, rendering the mutated form of Rap1a always active and unable to be downregulated by Rap1Gap. 25 Compared with LacZ (β-galactosidase)-treated Figure 5 . Gcgr (glucagon receptor)-cAMP regulates PCSK9 (proprotein convertase subtilisin/kexin type 9) and LDLR (low-density lipoprotein receptor) through Epac2 (exchange protein activated by cAMP-2). AML12 (alpha mouse liver 12) hepatocytes (HCs) were transfected with scrambled control (scr) or small interfering RNA against Epac2 (si-Epac2). Seventy-two hours later, cells were incubated with forskolin (Fors) and dexamethasone (Dex) for 6 h in serum-free media and Epac2 (Rapgef4 [rap guanine nucleotide exchange factor 4]) mRNA (A), PCSK9 and β-actin protein levels (B), and Pcsk9 mRNA was analyzed (C). Densitometric quantification of the immunoblot data is shown in the graph. D, Similar to (A-C) except that the cells were treated with or without Fors and Dex for 24 h in serum-free media. Secreted PCSK9 levels in culture media were analyzed by ELISA and normalized to intracellular protein concentration. Data are presented as arbitrary units (AU) relative to control. E and F, AML12 HCs were transfected with a plasmid containing short hairpin RNA against Epac2 (sh-Epac2) or the control plasmid (sh-con). Seventy-two hours later, cells were incubated with Fors and Dex for 24 h in serum-free media and LDLR, and β-actin protein levels were analyzed (E). Densitometric quantification of the immunoblot data is shown in the graph. F, Similar to (C) except that Ldlr mRNA was assayed. G, Wild-type primary HCs were treated with Epac activator 8-pCPT-2-O-Me-cAMP-AM or vehicle (Veh) in serum-free medium for 24 h. Secreted PCSK9 levels in culture media were analyzed by ELISA and normalized to intracellular protein concentration. Data is presented as AU relative to control. n=3-6 wells of cells per group, mean±SEM, *P<0.05; by unpaired, 2-tailed Student t test; Mann-Whitney U test or 1-way ANOVA. Figure 6 . Inhibition of hepatic Rap1 (ras-related protein-1) increases plasma PCSK9 (proprotein convertase subtilisin/kexin type 9), decreases hepatic LDLR (low-density lipoprotein receptor) protein, and increases plasma total cholesterol (TC) and LDL-C (LDL cholesterol) in diet-induced obese (DIO) mice. A, AML12 (alpha mouse liver 12) hepatocytes (HCs) were transfected with a plasmid containing short hairpin RNA against Rap1a (sh-Rap1a) or the control plasmid (sh-con). Seventy-two hours later, cells were incubated with forskolin and dexamethasone for 6 h in serum-free media and PCSK9, and β-actin protein levels were analyzed (left), and Rap1a and Pcsk9 mRNA levels were measured (right). Densitometric quantification of the immunoblot data is shown in the graph. n=4 wells of cells per group, mean±SEM, *P<0.05; by unpaired, 2-tailed Student t test. B-F, Twenty-week-old DIO mice were injected with adenovirus vectors containing LacZ (β-galactosidase) or Rap1Gap (rap1 GTPase activating protein) expression cassettes. Plasma PCSK9 (B), liver LDLR and Hsp90 (heat shock protein 90; loading control) protein (C), plasma TC levels were measured (D), and plasma lipoproteins were separated by fast protein liquid chromatography (E). Densitometric quantification of the immunoblot data is shown in the graph. F, Liver Ldlr, Pcsk9, Hmgcr, and Srebf2 mRNA levels were analyzed. n=7, mean±SEM, *P<0.05; by unpaired, 2-tailed Student t test. HDL indicates high-density lipoprotein; and VLDL, very low-density lipoprotein. Figure 7 . Activation of glucagon (Gluc) signaling regulates PCSK9 (proprotein convertase subtilisin/kexin type 9) independent of LDLR (low-density lipoprotein receptor) and by enhancing the lysosome-mediated degradation of PCSK9. A, Wild-type (WT) or Ldlr −/− primary hepatocytes (HCs) were transfected with empty control (sh-con) or short hairpin RNA targeting the Gcgr (glucagon receptor; sh-Gcgr) plasmids. 72 h later, cells were incubated with forskolin (Fors) and dexamethasone (Dex) for 24 h in serum-free media and secreted PCSK9 levels in culture media was analyzed by ELISA and normalized to intracellular protein concentration. Data are presented as arbitrary units (AU) relative to control. B, Ldlr −/− primary HCs were incubated with Fors and Dex or vehicle (Veh) for 5 or 24 h in serum-free media. Intracellular or secreted PCSK9 protein levels were analyzed. Ponceau S staining was used as the loading control in bottom blot. Densitometric quantification of the immunoblot data is shown in the graph. C, WT primary HCs were treated with glucagon (Gluc) or Veh in serum-free media for the indicated time periods, and Pcsk9 mRNA was analyzed. D, Primary HCs preincubated with or without Gluc for 2 h were then treated with cycloheximide (cyclo; 4 µg/mL) for the indicated time points, and PCSK9 and β-actin levels were analyzed. Densitometric quantification of PCSK9/β-actin data relative to Veh-treated cells is shown in the bar graph. E, Primary HCs were pretreated for 30 min with or without chloroquine or ammonium chloride (NH 4 Cl) and then incubated with Veh control (Con) or Fors and Dex for 5 h. Cell lysates were probed for PCSK9 and β-actin by immunoblot. Densitometric quantification of the immunoblot data is shown in the graph. n=3-4 wells of cells per group, mean±SEM, *P<0.05; by unpaired, 2-tailed Student t test; Mann-Whitney U test; 1-way ANOVA or 2-way ANOVA.
control, in adeno-CA-Rap1a-treated DIO mice plasma PCSK9 (185±28 versus 112±15 ng/mL) and total cholesterol levels (142±15 versus 101±8 mg/dL) decreased without a change in the mRNA levels of hepatic Pcsk9, Hmgcr, or Srebf2 (Online Figure X) . Similar results were obtained when WT lean mice were injected with adeno-CA-Rap1a (Online Figure XI) . These data show that Rap1a regulates hepatic and plasma PCSK9, plasma total cholesterol and LDL-C without affecting Pcsk9 or Ldlr mRNA levels.
Glucagon Signaling Regulates PCSK9 Protein Stability
Previous studies have shown that clearance of serum PCSK9 is mediated through LDLR-dependent uptake, suggesting reciprocal regulation between these proteins. 44 To understand the involvement of LDLR in glucagon signaling-mediated regulation of PCSK9, we silenced Gcgr in LDLR knockout hepatocytes. We observed that sh-Gcgr treatment increased PCSK9 levels in LDLR deficient primary hepatocytes ( Figure 7A ). Moreover, similar to WT hepatocytes, increasing intracellular cAMP levels by forskolin and dexamethasone treatment resulted in decreased intracellular and secreted PCSK9 levels in LDLR knockout hepatocytes ( Figure 7B ). Thus, glucagon regulates PCSK9 independently of LDLR.
In the next set of experiments, we found that glucagon treatment did not affect Pcsk9 mRNA levels ( Figure 7C ) at time points when PCSK9 protein was decreased ( Figure 4A ), suggesting that the regulation is posttranscriptional. Therefore, to understand whether glucagon affects PCSK9 stability, we treated cells with cycloheximide to inhibit new protein translation and found significantly decreased PCSK9 protein in the presence of glucagon, suggesting enhanced degradation ( Figure 7D ). Previous work reported the involvement of lysosomal degradation in PCSK9 regulation. 45 In this context, we found that disruption of lysosomal function via chloroquine or ammonium chloride pretreatment prevented the decrease in PCSK9 protein conferred by forskolin and dexamethasone treatment in primary hepatocytes ( Figure 7E ). Collectively, these data show that activation of Gcgr signaling enhances the lysosome-mediated degradation of PCSK9 in an LDLR-independent manner.
Discussion
The discovery of PCSK9 as a key regulator of LDLR recycling and plasma LDL-C gained extensive attention and rapidly translated into clinical practice. 46 Monoclonal antibodies against PCSK9 are now approved for use in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional LDL-C lowering therapy. However, monoclonal antibodies can only block secreted PCSK9, and previous work implicated that intracellular PCSK9 may regulate lipoprotein metabolism before secretion. 33 Therefore, identification of pathways which regulate PCSK9 homeostasis within the cell is important. Although the transcriptional regulation of PCSK9 has been well-studied, the posttranscriptional regulation of PCSK9 is largely unknown. 35, 47, 48 In this context, our findings suggesting that a hepatocyte Gcgr-Epac2-Rap1 pathway regulating PCSK9 and LDLR protein levels provide new insight into the biology of PCSK9 (Online Figure XII) .
Hyperglucagonemia and unopposed glucagon action have been emphasized as critical factors responsible for enhanced hepatic glucose production in T2D. 15, 49 Indeed, our previous work uncovered new Gcgr signaling pathways in hepatocytes that contribute to both increased hepatic glucose production and impaired insulin receptor signaling. 50, 51 Blocking glucagon action decreases hyperglycemia in T2D patients and improves glycemic control and decreases insulin requirement in patients with type 1 diabetes mellitus. 18, 52 Ironically, glucagon action has been shown to exert beneficial effects in metabolism because it also participates in the control of energy expenditure and lipid homeostasis. 53 Glucagon administration was shown to lower plasma cholesterol in rodents, dogs, and human subjects. 14, [54] [55] [56] Moreover, studies in dogs undergoing subtotal pancreatectomy have revealed increased plasma cholesterol levels which were reversed by glucagon administration, further supporting the link between glucagon action and cholesterol homeostasis. 57 In this context, recent work describing novel preclinical applications of glucagon agonism in combination with other antidiabetic agents have demonstrated the potential of capturing the benefits of glucagon action for the treatment of metabolic disease; however, the molecular mechanisms remain poorly understood. 58, 59 Various mouse models and human data have provided evidence that blocking glucagon action results in increased plasma LDL-C levels. 13, 18, 31, 32 Although 1 study attributed this increase to elevated rates of lipogenesis, another report suggested that the mechanism is through an increase in intestinal cholesterol absorption. 32, 60 In contrast, our results suggest a novel role for PCSK9 and LDLR-mediated control of plasma LDL-C when hepatic Gcgr is silenced, which is consistent with prior reports showing regulation of LDLR by glucagon. 61 It is possible that differences in experimental design may have contributed to the different outcomes in these studies, such as differences in the mouse models (db/db or mice expressing human Gcgr versus DIO or WT lean mice) and diets used. Interestingly, a recent report using DIO mice treated with dual Glp-1 (glucagon-like peptide-1) and Gcgr agonist have shown decreased PCSK9, increased hepatic LDLR, and a concomitant decrease in plasma LDL-C which was attributed to Gcgr action because activation of Glp-1 receptors alone had no effect on these parameters. 62 Moreover, Han et al 32 reported increases in plasma triglycerides, whereas plasma triglycerides levels were similar in our experimental models. Nevertheless, it is possible that in the context of severe insulin resistance (db/ db) or when glucagon action is inhibited using certain Gcgr antagonists in mice expressing human Gcgr, increased lipogenesis or intestinal cholesterol absorption may become dominant and mask the effect of glucagon signaling on PCSK9.
Epac exists as 2 isoforms, Epac1 and Epac2, which are coded by different genes. 37 Although Epac1 is expressed ubiquitously, the expression of Epac2 is mainly found in the liver, pancreas, and the central nervous system. 63 Interestingly, mice lacking Epac1 and Epac2 exhibit metabolic defects, including obesity and glucose intolerance. [64] [65] [66] Additionally, activation of Epac2 and Rap1 has been linked to incretin and sulfonylurea-mediated insulin secretion, suggesting a possible beneficial effect of activating Epac2 or Rap1 pathway for T2D management. 65, 67 Our results reveal another potential beneficial effect of the aforementioned pathway in metabolism, namely lowering PCSK9 and thereby contributing to plasma cholesterol regulation. The data presented here suggest that activation of Gcgr signaling regulates PCSK9 protein stability without changing the level of its mRNA. Our time course experiments in glucagon-stimulated hepatocytes revealed that Pcsk9 mRNA levels were unchanged at time points when PCSK9 protein was decreased ( Figure 7C ). However, it is possible that during extended periods of fasting and sustained activation of Gcgr, Pcsk9 mRNA may be downregulated, which could contribute to lower PCSK9 expression. 22, 68 Nonetheless, in the model described here, we propose Epac2 and Rap1 as the mediators of glucagon's effect on lysosome-mediated degradation of PCSK9. Previous work has shown that PCSK9 is routed to lysosomes for degradation, and this effect is independent of LDLR. 69 Interestingly, glucagon and an increase in intracellular cAMP have long been reported to stimulate lysosomal degradation of many proteins; however, the exact mechanism is unknown.
70,71
Moreover, Rap1 protein was shown to localize to late endosomes and lysosomes, suggesting its potential role in the regulation of lysosome function. 72 Likewise, actin cytoskeleton dynamics were suggested to play essential roles in different forms of intracellular trafficking, including the vesicle trafficking between late endosomes and lysosomes. 73, 74 In this regard, Rap1 has been implicated in the regulation of multiple processes associated with actin cytoskeletal dynamics, including integrin-and cadherin-mediated cell adhesion. [75] [76] [77] Therefore, it is possible that Rap1 promotes the lysosomal degradation of PCSK9 through its effects on cytoskeletal organization.
In summary, the present study elucidates a previously unrecognized role for Gcgr-Epac2-Rap1 pathway in the regulation of plasma LDL-C metabolism through PCSK9. Our findings increase our knowledge of PCSK9 biology and raise the possibility of targeted Epac2-Rap1 activation as a new therapeutic strategy to lower plasma LDL-C levels. 
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